The authors have evaluated the behaviour of protein C activity, factor X and factor VII coagulant activity, and serum lipoprotein(a) before and after haemodialytic treatment in the plasma of patients on maintenance haemodialysis. The plasma level of protein C activity, depressed before haemodialysis, significantly increased during the course of haemodialysis; factor X and factor VII increased as well despite heparinization; serum lipoprotein(a) was abnormally elevated before haemodialysis and did not change after haemodialysis. In vitro incubation (30' at 37 degrees C) of uremic and healthy blood samples resulted in a decrease of serum lipoprotein(a) concentration. After heparin addition (final concentration 0.5 U/ml) lipoprotein(a) became higher in uremic blood only.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Introduction: Recently, interest has been growing in lipoprotein(a) (Lp(a)) as an independent risk factor for cardiovascular diseases. European Society of Cardiology (ESC) recommends a single measurement of Lp(a) concentration as a guide to determining cardiovascular risk group and appropriate treatment. Although initially assumed to be genetically determined, a growing number of reports indicate that Lp(a) concentration may change over time.
View Article and Find Full Text PDFGenetic association of circulating lipids and lipid-lowering drug targets with vascular calcification.
Atherosclerosis
February 2025
National Clinical Research Center for Chinese Medicine Cardiology, Xiyuan Hospital, Chinese Academy of Chinese Medical Sciences, Beijing, 100091, China. Electronic address:
Background And Aims: Vascular calcification (VC) significantly increases the incidence and mortality of many diseases. The causal relationships of dyslipidaemia and lipid-lowering drug use with VC severity remain unclear. This study explores the genetic causal associations of different circulating lipids and lipid-lowering drug targets with coronary artery calcification (CAC) and abdominal aortic artery calcification (AAC).
View Article and Find Full Text PDFElevated lipoprotein(a) levels in rheumatic heart valvular disease: A new link?
Lipids
February 2025
Department of Cardiology, Basaksehir Cam and Sakura City Hospital, Istanbul, Turkey.
Rheumatic heart valvular disease (RHVD) is primarily characterized by immune-mediated damage following infection with Streptococcus pyogenes, leading to inflammation and subsequent valvular dysfunction. Traditionally, the focus has been on the immunological aspects of this disease; however, emerging evidence suggests that lipoprotein(a) [Lp(a)] may play a crucial role not only in atherosclerosis but also in the pathophysiology of calcific aortic valve disease. Given the inflammatory nature of RHVD and the pro-inflammatory and pro-calcific properties of Lp(a), this study aimed to investigate the relationship between serum Lp(a) levels and the severity of RHVD.
View Article and Find Full Text PDFElevated Lp(a) and its association with cardiac fibrosis in group II pulmonary hypertension patients.
Future Cardiol
February 2025
Department of Medicine, Sultan Qaboos University Hospital, Muscat, Oman.
Background: Group II Pulmonary Hypertension (PH) secondary to Heart Failure with preserved Ejection Fraction (HFpEF) is associated with significant morbidity and mortality. Lipoprotein(a) [Lp(a)] is a novel biomarker implicated in cardiovascular pathology, yet its role in myocardial fibrosis within this population remains underexplored. This study investigates the association between elevated Lp(a) levels and cardiac fibrosis to improve understanding of its prognostic and diagnostic utility.
View Article and Find Full Text PDFStatins-Their Effect on Lipoprotein(a) Levels.
Rev Cardiovasc Med
January 2025
Department of Clinical and Experimental Pharmacology, Faculty of Medicine, Medical University of Warsaw, 02-097 Warsaw, Poland.
Lipoprotein(a) (Lp(a)) serum concentration plays a crucial role as a risk factor in cardiovascular diseases and is gaining more and more attention. Patients with elevated lipoprotein(a) levels are often prescribed statins as they also have high concentrations of low-density lipoprotein cholesterol (LDL-C). Statins are drugs that successfully decrease LDL-C, but their effectiveness in Lp(a) levels reduction is uncertain.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!